Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.
Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.
Soleno's stock dipped after a PWS patient died. Company & doctor say death (pulmonary embolus) was unrelated to VYKAT XR, citing patient's co-morbidities & PWS risks.
